SCHEMBL4333228

SCHEMBL4333228

COc1ccc(-c2cc3cc(F)ccc3[nH]2)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.58
KDM4E B2RXH2 6/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 3/20 0.47
AHR P35869 2/20 0.47
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPT P10636 6/20 0.46
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
USP2 O75604 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10796083 0.80 RAB9A (0.67) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL30770801 0.80 RAB9A (0.67) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL30869753 0.79 CYP1A1 (0.68) CYP1A1KDM4EALDH1A1HPGDMEN1
SCHEMBL19914883 0.77 CYP1A1 (0.67) CYP1A1KDM4EALDH1A1HPGDMEN1
SCHEMBL4568292 0.77 CYP1A1 (0.51) CYP1A1KDM4EALDH1A1HPGDAHR
SCHEMBL6118259 0.76 KDM4E (0.72) CYP1A1KDM4EALDH1A1HPGDMEN1
SCHEMBL6116903 0.75 TNKS (0.48) CYP1A1KDM4EALDH1A1HPGDMEN1
SCHEMBL30424886 0.74 AMY1A (0.63) KDM4EALDH1A1HPGDAHRMEN1
SCHEMBL10831846 0.74 CYP1A1 (0.61) CYP1A1KDM4EALDH1A1HPGDMEN1
SCHEMBL10176209 0.73 TUBB4A (0.47) CYP1A1KDM4EALDH1A1HPGDAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264384-A1 INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF NUADA, INC. (US) 2009-10-22 US disclosed
US-20080319044-A1 Compounds and Methods of Use Thereof NUADA, LLC (US) 2008-12-25 US disclosed
WO-2007134169-A9 INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF NUADA LLC (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264384-A1 INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF TNF, NFKBIA, IL6 CYP1A1 1143/4885KDM4E 2408/4885ALDH1A1 531/4885
US-20080319044-A1 Compounds and Methods of Use Thereof TNF, LITAF, LTA CYP1A1 2095/4885KDM4E 3995/4885ALDH1A1 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.